
Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.
Plaque psoriasis experts explore recent advancements in treatment options, patient experiences, and the potential of novel oral systemic therapies to reduce the burden of this prevalent chronic condition.






